📊 APGE Key Takeaways
Is Apogee Therapeutics, Inc. (APGE) a Good Investment?
Apogee is a pre-commercial biotech company with no revenue and substantial cash burn (-$60.7M free cash flow) despite maintaining a strong balance sheet with $451.8M in cash. While the company has 7+ years of runway at current burn rates, the absence of any revenue generation, persistent operating losses (-$82.8M), and negative profitability metrics indicate a high-risk venture dependent entirely on unproven pipeline success.
Apogee Therapeutics has weak current profitability, with no revenue, large operating losses, and deeply negative free cash flow, which is typical of a clinical-stage biotech but still a major fundamental constraint. The balance sheet is a meaningful offset: very high liquidity, minimal liabilities, and a large asset base provide runway to fund development without obvious near-term balance sheet stress. Fundamentally, the story depends on whether pipeline progress eventually converts cash burn into durable revenue growth.
Apogee Therapeutics, Inc. Key Strengths (APGE)
- Substantial cash reserves of $451.8M providing multi-year runway for clinical development
- Fortress balance sheet with minimal liabilities ($37.9M) relative to assets ($1.3B), eliminating near-term insolvency risk
- Exceptional liquidity position (32.59x current ratio) enabling flexibility for R&D investments or pivot strategies
- Exceptionally strong liquidity, with 26.57x current and quick ratios indicating ample near-term funding capacity
- Very low balance-sheet leverage, with only $33.25M of liabilities against $937.13M of assets
- Large cash position of $131.55M plus a substantial asset base supports ongoing R&D execution
APGE Stock Risks: Apogee Therapeutics, Inc. Investment Risks
- Complete absence of revenue indicating pre-commercial stage with unproven commercialization capability
- Severe cash burn rate ($60.7M negative FCF) with no path to profitability visible in current fundamentals
- Deteriorating diluted EPS (-27.9% YoY decline) suggesting significant share dilution from equity financing
- Heavy insider trading activity (12 Form 4 filings in 90 days) with unclear directional intent
- No revenue base, leaving the company fully dependent on external funding and pipeline advancement
- Heavy losses, including -$285.60M operating income and -$232.60M free cash flow, indicate significant cash burn
- Worsening diluted EPS and negative ROA show weak capital efficiency and limited visibility on profitability
Key Metrics to Watch
- Clinical pipeline advancement and regulatory milestones (FDA approvals/rejections)
- Monthly cash burn rate trajectory and time to cash runway depletion
- Gross margin and operating margin upon revenue generation (if achieved)
- Quarterly operating cash burn and free cash flow trend
- Any emergence of revenue or major improvement in operating loss as pipeline programs mature
Apogee Therapeutics, Inc. (APGE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 32.59x current ratio provides a solid financial cushion.
APGE Profit Margin, ROE & Profitability Analysis
APGE vs Healthcare Sector: How Apogee Therapeutics, Inc. Compares
How Apogee Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Apogee Therapeutics, Inc. Stock Overvalued? APGE Valuation Analysis 2026
Based on fundamental analysis, Apogee Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Apogee Therapeutics, Inc. Balance Sheet: APGE Debt, Cash & Liquidity
APGE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Apogee Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.36 indicates the company is currently unprofitable.
APGE Revenue Growth, EPS Growth & YoY Performance
Apogee Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
APGE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Apogee Therapeutics, Inc. (CIK: 0001974640)
📋 Recent SEC Filings
❓ Frequently Asked Questions about APGE
What is the AI rating for APGE?
Apogee Therapeutics, Inc. (APGE) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are APGE's key strengths?
Claude: Substantial cash reserves of $451.8M providing multi-year runway for clinical development. Fortress balance sheet with minimal liabilities ($37.9M) relative to assets ($1.3B), eliminating near-term insolvency risk. ChatGPT: Exceptionally strong liquidity, with 26.57x current and quick ratios indicating ample near-term funding capacity. Very low balance-sheet leverage, with only $33.25M of liabilities against $937.13M of assets.
What are the risks of investing in APGE?
Claude: Complete absence of revenue indicating pre-commercial stage with unproven commercialization capability. Severe cash burn rate ($60.7M negative FCF) with no path to profitability visible in current fundamentals. ChatGPT: No revenue base, leaving the company fully dependent on external funding and pipeline advancement. Heavy losses, including -$285.60M operating income and -$232.60M free cash flow, indicate significant cash burn.
What is APGE's revenue and growth?
Apogee Therapeutics, Inc. reported revenue of N/A.
Does APGE pay dividends?
Apogee Therapeutics, Inc. does not currently pay dividends.
Where can I find APGE SEC filings?
Official SEC filings for Apogee Therapeutics, Inc. (CIK: 0001974640) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is APGE's EPS?
Apogee Therapeutics, Inc. has a diluted EPS of $-1.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is APGE's fundamental grade?
Based on our AI fundamental analysis in June 2026, Apogee Therapeutics, Inc. has a C grade with 71% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is APGE stock overvalued or undervalued?
Valuation metrics for APGE: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is APGE's AI grade for 2026?
Our dual AI analysis gives Apogee Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is APGE's free cash flow?
Apogee Therapeutics, Inc.'s operating cash flow is $-55.6M, with capital expenditures of $5.1M.
How does APGE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 32.59 (avg: 2).